{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:28Z","timestamp":1761171868340,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":3948,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.farma.2010.05.008","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T04:36:18Z","timestamp":1290227778000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tasa de mutaciones genot\u00edpicas y resistencia a antirretrovirales en un hospital general"],"prefix":"10.1016","volume":"35","author":[{"given":"L.C.","family":"Fern\u00e1ndez Lis\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Fern\u00e1ndez Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Romero Chala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2010.05.008_bib0005","first-page":"573","article-title":"Use study of tenofovir DF in highly active anti-retroviral therapy","volume":"23","author":"Fern\u00e1ndez Lis\u00f3n","year":"2006","journal-title":"An Med Interna."},{"key":"10.1016\/j.farma.2010.05.008_bib0010","first-page":"55","article-title":"Resistencias al tratamiento antirretroviral","volume":"28","author":"Mart\u00edn-Conde","year":"2004","journal-title":"Farm Hosp."},{"key":"10.1016\/j.farma.2010.05.008_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1130-6343(07)75707-0","article-title":"Influencia de las pruebas de resistencias a antirretrovirales sobre la efectividad del tratamiento en pacientes con infecci\u00f3n por VIH y fracaso virol\u00f3gico","volume":"31","author":"Gamero","year":"2007","journal-title":"Farm Hosp."},{"key":"10.1016\/j.farma.2010.05.008_bib0020","first-page":"39","article-title":"HIV-1 genotypic drug resistance interpretation rules-2009 Spanish guidelines","volume":"11","author":"De Mendoza","year":"2009","journal-title":"AIDS Rev."},{"key":"10.1016\/j.farma.2010.05.008_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: Recomendations of the International AIDS Society USA Panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA."},{"key":"10.1016\/j.farma.2010.05.008_bib0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/135965350400900619","article-title":"Updated European recommendations for the clinical use of HIV drug resistance testing","volume":"9","author":"Vandamme","year":"2004","journal-title":"Antivir Ther."},{"key":"10.1016\/j.farma.2010.05.008_bib0035","unstructured":"Panel de expertos de GESIDA y Plan Nacional sobre el SIDA. Recomendaciones GESIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. [Actualizado febrero 2009; consultado 23\/11\/2009]. Disponible en http:\/\/www.seimc.org\/"},{"key":"10.1016\/j.farma.2010.05.008_bib0040","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/QAD.0b013e3282f0b685","article-title":"Transmission of HIV-1 drug resistance in Switzerland: a 10 year molecular epidemiology survey","volume":"21","author":"Yerli","year":"2007","journal-title":"AIDS."},{"key":"10.1016\/j.farma.2010.05.008_bib0045","first-page":"346","article-title":"Epidemiolog\u00eda de las resistencias genot\u00edpicas del VIH-1 en Valencia. Estudio de 4 a\u00f1os","volume":"20","author":"Molina","year":"2007","journal-title":"Rev Esp Quimioterap."},{"key":"10.1016\/j.farma.2010.05.008_bib0050","first-page":"145","article-title":"Study of resistance using the TRUGENE HIV-1 genotyping system and analysis of agreement between rule-based algorithms and virtual phenotyping","volume":"23","author":"Nogales","year":"2005","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.farma.2010.05.008_bib0055","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Should resistance testing be performed for treatment-naive HIV infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.farma.2010.05.008_bib0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eimc.2008.02.007","article-title":"Genotypic resistance in HIV-1-infected patients with persistent low-level viremia","volume":"27","author":"Parra-Ruiz","year":"2009","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.farma.2010.05.008_bib0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.qai.0000174929.87015.d6","article-title":"HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia","volume":"40","author":"Napravnik","year":"2005","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.farma.2010.05.008_bib0070","first-page":"203","article-title":"Prevalencia de la resistencia genot\u00edpica a los f\u00e1rmacos antirretrovirales en pacientes VIH positivos en la provincia de Cuenca","volume":"20","author":"Rodr\u00edguez-Escudero","year":"2007","journal-title":"Rev Esp Quimioterap."},{"key":"10.1016\/j.farma.2010.05.008_bib0075","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.farma.2010.05.008_bib0080","unstructured":"McColl D, Margot N, Chuang SM, Chen SS, Miller M. Final week 144 resistance analisys of study 934: No K65R detected and lower frequency of M184V on tenofovir DF + emtricitabine + efavirenz compared to combivir + efavirenz. 11th European AIDS Conference, Madrid, 2007; P3.1\/08."},{"key":"10.1016\/j.farma.2010.05.008_bib0085","first-page":"138","article-title":"Virological characterization of HIV strains in recent seroconverters in Spain","volume":"13","author":"De Mendoza","year":"2008","journal-title":"Antivir Ther."},{"key":"10.1016\/j.farma.2010.05.008_bib0090","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple drug therapy. AIDS Clinical trials Group Study 343 Team","volume":"339","author":"Havlir","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.farma.2010.05.008_bib0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type-1:2003 recommendations of an International AIDS Society-USA Panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.farma.2010.05.008_bib0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002030-200501280-00007","article-title":"Atazanavir plus ritonavir or saquinavir, and lopinavir\/ritonavir in patients experiencing multiple virological failures","volume":"19","author":"Johnson","year":"2005","journal-title":"AIDS."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634310002230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634310002230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:15:42Z","timestamp":1761106542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634310002230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1130634310002230"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2010.05.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tasa de mutaciones genot\u00edpicas y resistencia a antirretrovirales en un hospital general","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2010.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 SEFH. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}